Dana-Farber Marathon Challenge
The Claudia Adams Barr Program in Innovative Cancer Research
Impact on Cancer Research World-wide
The Barr Program has had tremendous impact because of its size
From 1987 to 2006, the Barr Program has distributed over $32 million in research funding to 113 investigators.
The Barr Program's effects are felt throughout the world of cancer research
- Several Barr Investigators who were supported early in their careers have already gone on to become tenured professors or department heads or division chiefs. These are the positions of greatest influence in cancer research and they show how the Barr Program continues to have a significant and ongoing impact in this area.
- Barr Investigators are now senior faculty members at some of the most prestigious academic institutions in the US. Alumni include:
- Michael Brenner, MD, Chief of Rheumatology, Brigham & Women's Hospital, Harvard Medical School
- Myles Brown, MD, Chief of the Division of Molecular and Cellular Oncology, Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
- Michael Caliguri, MD, Director of the James Cancer Center at Ohio State University
- James Ferrara, MD, Director Bone Marrow Transplant, University of Michigan Caner Center
- David E. Fisher, MD, PhD, Professor of Pediatrics, Dana-Farber Cancer Institute, Harvard Medical School
- Dana Gabuzda, MD, Professor of Neurology, Dana-Farber Cancer Institute, Harvard Medical School
- James Griffin, MD, Chief of Medical Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
- Massimo Loda, MD, Professor of Pathology, Dana-Farber Cancer Institute, Harvard Medical School
- Barrett Rollins, MD, PhD, Chief Scientific Officer, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
- David Rowitch, MD, PhD, Chief of Neonatology, University of California San Francisco
- Pamela Silver, PhD, Professor of Systems Biology, Harvard Medical School
- Bruce Spiegelman, PhD, Professor of Cell Biology, Dana-Farber Cancer Institute, Harvard Medical School, member of the National Academy of Sciences
- Barr Investigators have international influence:
- Christopher Rudd, PhD, Chief of Hematology, Hammersmith Hospital, Imperial College, London, UK
- Thomas Wileman, PhD, Head of Immunology and Pathology, Institute for Animal Health, Surrey, UK
- Barr Investigators also lead cancer research programs in pharmaceutical and biotechnology companies:
- Hans Reiser, MD, VP for Biology, Gilead Sciences
- William Sellers, MD, Global Head Oncology, Novartis
